Literature DB >> 30543306

Functional interaction between PDGFβ and GluN2B-containing NMDA receptors in smooth muscle cell proliferation and migration in pulmonary arterial hypertension.

Marceau Quatredeniers1,2, Morad K Nakhleh1,2, Sébastien J Dumas1,2, Audrey Courboulin1,2, Maria C Vinhas1,2, Fabrice Antigny1,2, Carole Phan1,2, Christophe Guignabert1,2, Imane Bendifallah1,2, Matthieu Vocelle1,2, Elie Fadel1,2, Peter Dorfmüller1,2, Marc Humbert1,2,3, Sylvia Cohen-Kaminsky1,2.   

Abstract

In this study, we explored the complex interactions between platelet-derived growth factor (PDGF) and N-methyl-d-aspartate receptor (NMDAR) and their effect on the excessive proliferation and migration of smooth muscle cells leading to obstructed arteries in pulmonary arterial hypertension (PAH). We report lower expression of glutamate receptor NMDA-type subunit 2B (GluN2B), a subunit composing NMDARs expected to affect cell survival/proliferation of pulmonary artery smooth muscle cells (PASMCs), in PAH patient lungs. PASMC exposure to PDGF-BB stimulated immediate increased levels of phosphorylated Src family kinases (SFKs) together with increased phosphorylated GluN2B (its active form) and cell surface relocalization, suggesting a cross talk between PDGFR-recruited SFKs and NMDAR. Selective inhibition of PDGFR-β or SFKs with imatinib or A-419259, respectively, on one hand, or with specific small-interfering RNAs (siRNAs) on the other hand, aborted PDGF-induced phosphorylation of GluN2B, thus validating the pathway. Selective inhibition of GluN2B using Rö25-6981 and silencing with specific siRNA, in the presence of PDGF-BB, significantly increased both migration and proliferation of PASMCs, thus strengthening the functional importance of the pathway. Together, these results indicate that GluN2B-type NMDAR activation may confer to PASMCs antiproliferative and antimigratory properties. The decreased levels of GluN2B observed in PAH pulmonary arteries could mediate the excessive proliferation of PASMCs, thus contributing to medial hyperplasia and PAH development.

Entities:  

Keywords:  -methyl--aspartate receptor; Src family kinases; platelet-derived growth factor; pulmonary arterial hypertension; pulmonary artery smooth muscle cell

Mesh:

Substances:

Year:  2018        PMID: 30543306     DOI: 10.1152/ajplung.00537.2017

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  5 in total

1.  Luteolin Ameliorates Experimental Pulmonary Arterial Hypertension via Suppressing Hippo-YAP/PI3K/AKT Signaling Pathway.

Authors:  Wanyun Zuo; Na Liu; Yunhong Zeng; Zhenghui Xiao; Keke Wu; Fan Yang; Biao Li; Qingqing Song; Yunbin Xiao; Qiming Liu
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

2.  Functional NMDA receptors are expressed by human pulmonary artery smooth muscle cells.

Authors:  Yi Na Dong; Fu-Chun Hsu; Cynthia J Koziol-White; Victoria Stepanova; Joseph Jude; Andrei Gritsiuta; Ryan Rue; Rosalind Mott; Douglas A Coulter; Reynold A Panettieri; Vera P Krymskaya; Hajime Takano; Elena A Goncharova; Dmitry A Goncharov; Douglas B Cines; David R Lynch
Journal:  Sci Rep       Date:  2021-04-15       Impact factor: 4.379

3.  TRIM32 inhibits the proliferation and migration of pulmonary artery smooth muscle cells through the inactivation of PI3K/Akt pathway in pulmonary arterial hypertension.

Authors:  Zhi Hu; Qiang Song; Hui Ma; Yaozhang Guo; Tingting Zhang; Hang Xie; Xiaohui Luo
Journal:  J Bioenerg Biomembr       Date:  2021-03-10       Impact factor: 2.945

4.  NMDAR in bladder smooth muscle is not a pharmacotherapy target for overactive bladder in mice.

Authors:  Xiang Xie; Chuang Luo; Jia Yu Liang; Run Huang; Jia Li Yang; Linlong Li; YangYang Li; Hongming Xing; Huan Chen
Journal:  PeerJ       Date:  2021-07-07       Impact factor: 2.984

5.  Integrated analysis of m6A mRNA methylation in rats with monocrotaline-induced pulmonary arterial hypertension.

Authors:  Yunhong Zeng; Ting Huang; Wanyun Zuo; Dan Wang; Yonghui Xie; Xun Wang; Zhenghui Xiao; Zhi Chen; Qiming Liu; Na Liu; Yunbin Xiao
Journal:  Aging (Albany NY)       Date:  2021-07-26       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.